{'fraction_non_alphanumeric': 0.05364868762618979, 'fraction_numerical': 0.04095760023074704, 'mean_word_length': 5.294010889292196, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AB0219 Impact of early diagnosis on long-term effectiveness of first-line anti-tnf-alpha treatment in rheumatoid arthritispatients

Objectives Aim of this work was to evaluate effectiveness and drug persistence of anti-tumour necrosis factor (TNF)-alpha therapies in early and late diagnosed rheumatoid arthritis (RA) patients naïve for biological disease-modifying antirheumatic drug (bDMARD) use. Methods Baseline and follow-up (FU) charts RA patients with disease onset later than 2002 and access to rheumatology care between January 2007 and December 2016 were reviewed until December 2017. All patients fulfilled 2010 ACR/EULAR classification criteria. At baseline, demographic, anamnestic and serological characteristics were collected. Based on lag time between onset of symptoms and definite diagnosis, RA patients were categorised into two groups: early diagnosed (less than 12 months) and late diagnosed (more than 12 months). Disease activity and treatment response were assessed every three months by Simplified Disease Activity Index (SDAI). Anti-TNF-alpha survival was defined as the length of time from initation to discontinuation of therapy due to loss of effectiveness over time. It was examined using Kaplan-Meier survival analysis. Results One hundred and fifteen RA patients (86.1% females, mean age 59.4) were included. The median disease duration between onset of symptoms and diagnosis was 25 months.20–43 68 patients (59.1%) were labelled as early diagnosed and 47 (40.9%) as late diagnosed. At baseline, no differences were found in age, gender, smoking habits, body mass index, and rheumatoid factor positivity. The most frequently used first-line anti-TNF drug was etanercept (30.4%), followed by adalimumab (20%), golimumab (18.3%), infliximab (16.5%), and certolizumab (14.8%). All patients received anti-TNF-alpha therapy in combination with csDMARD (methotrexate or leflunomide). Average steroid dosage was 5 mg/day of prednisone (or its equivalent) over time. The median time to initation of any anti-TNF-alpha treatment after definite diagnosis was 18 months.6–30 Kaplan-Meier analysis showed a lower anti-TNF-alpha discontinuation rate for early diagnosed RA patients than late diagnosed (9 year retention rate of 29.5% and 12.7%, respectively; p=0.0049) (figure 1).Abstract AB0219 – Figure 1 Conclusions This small real-world retrospective, observational, cohort study demonstrates that early diagnosis of RA provides higher retention rate of anti-TNF-alpha treatment as first-line bDMARD. References [1] Aletaha D, Neogi T, Silman AJ, et al. 2010Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum2010 Sep;62(9):2569–81. [2] Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis. 2012Jul;71(7):1190–6. [3] Wijbrandts CA, Tak PP. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc. 2017Jul;92(7):1129–1143. [4] Soubrier M, Pereira B, Frayssac T, Fan A, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice – Auvergne experience. Int J Rheum Dis. 2017Sep 13. Disclosure of Interest None declared